Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy

被引：0
|
作者：
Blackwell, K. L.
Burstein, H. J.
Sledge, G. W.
Stein, S.
Ellis, C.
Casey, M.
Baselga, J.
O'Shaughnessy, J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
[4] GlaxoSmithKline Inc, Collegeville, PA USA
[5] Vall Hebron Univ Hosp, Barcelona, Spain
[6] US Oncol, Dallas, TX USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：499S / 499S
页数：1
相关论文
共 50 条
  • [21] Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
    Visani, L.
    Ratosa, I.
    Ribnikar, D.
    Becherini, C.
    Bertini, N.
    Bonaparte, I.
    Stefanovski, D.
    Dobnikar, N.
    Desideri, I.
    Mattioli, C.
    Valzano, M.
    Banini, M.
    Salvestrini, V.
    Bernini, M.
    Tommasi, C.
    Nori, J.
    Orzalesi, L.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 60 - 61
  • [22] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
  • [23] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    J. Gavilá
    J. De La Haba
    B. Bermejo
    Á. Rodríguez-Lescure
    A. Antón
    E. Ciruelos
    J. Brunet
    E. Muñoz-Couselo
    M. Santisteban
    C. A. Rodríguez Sánchez
    A. Santaballa
    P. Sánchez Rovira
    J. Á. García Sáenz
    M. Ruiz-Borrego
    A. L. Guerrero-Zotano
    M. Huerta
    A. Cotes-Sanchís
    J. Lao Romera
    E. Aguirre
    J. Cortés
    A. Llombart-Cussac
    Clinical and Translational Oncology, 2020, 22 : 420 - 428
  • [24] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Ye Yuan
    Xumei Liu
    Yi Cai
    Wenyuan Li
    Systematic Reviews, 11
  • [25] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Yuan, Ye
    Liu, Xumei
    Cai, Yi
    Li, Wenyuan
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [26] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
    Baez-Vallecillo, L.
    Raghavendra, A. Singareeka
    Hess, K.
    Moulder, S. L.
    Tripathy, D.
    Valero, V.
    Murthy, R. K.
    CANCER RESEARCH, 2017, 77
  • [27] Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
    Waks, Adrienne G.
    Keenan, Tanya E.
    Li, Tianyu
    Tayob, Nabihah
    Wulf, Gerburg M.
    Richardson, Edward T.
    Attaya, Victoria
    Anderson, Leilani
    Mittendorf, Elizabeth A.
    Overmoyer, Beth
    Winer, Eric P.
    Krop, Ian E.
    Agudo, Judith
    Van Allen, Eliezer M.
    Tolaney, Sara M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [28] A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
    Paridaens, R.
    Rixe, O.
    Pinel, M. C.
    Wildiers, H.
    Zorza, G.
    Ferre, P.
    Roche, H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 503 - 511
  • [29] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
  • [30] Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines
    Canonici, Alexandra
    Pedersen, Kasper
    Browne, Brigid
    McDermott, Martina
    Walsh, Naoml
    Crown, John
    O'Donovan, Norma
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345